

Covalon Announces Conference Call to Discuss Fourth Quarter and Year End Fiscal 2022 Financial Results

MISSISSAUGA, ON, Jan. 23, 2023 /CNW/ - Covalon Technologies Ltd. (the "Company" or "Covalon") (TSXV: COV) (OTCQX: CVALF), an advanced medical technologies company, will release its Q4 and year end Fiscal 2022 financial results on Wednesday, January 25th, 2023, after markets close. A conference call and webcast to discuss the financial results will be held on Thursday, January 26th, 2023 at 9:00am EST.

To view, listen to, and participate in the live webcast, please follow the link below:

<https://app.webinar.net/L5Gbg9PmNYo>

To listen and participate via the conference call, please dial:

North American Toll-Free: 1-888-664-6392
Local (Toronto): 416-764-8659
Confirmation Number: 24078707

Participants will be able to ask questions of Company management during the Q&A portion of the conference call either by asking them on the call or by submitting them using the chat function on the webcast.

A recording of the call will be available by calling 1-888-390-0541 or 416-764-8677 and entering the encore replay entry code 078707# until February 9th, 2023. A recording of the call will also be available on www.covalon.com under News & Events on the Investors tab.

Copies of Covalon's financial statements and MD&A can be obtained on SEDAR at www.sedar.com and under Sedar Filings on the Investors tab of Covalon's website.

Website: <https://covalon.com>
Twitter: [@covalon](https://twitter.com/covalon)

About Covalon

Covalon Technologies Ltd. is a researcher, developer, manufacturer, and marketer of patent-protected medical products that improve patient outcomes and save lives in the areas of advanced wound care, infection management and surgical procedures. Covalon leverages its patented medical technology platforms and expertise in two ways: (i) by developing products that are sold under Covalon's name; and (ii) by developing and commercializing medical products for other medical companies under development and license contracts. The Company is listed on the TSX Venture Exchange, having the symbol COV and trades on the OTCQX Market under the symbol CVALF. To learn more about Covalon, visit our website at www.covalon.com

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

This news release may contain forward-looking statements which reflect the Company's current expectations regarding future events. The forward-looking statements are often, but not always, identified by the use of words such as "seek", "anticipate", "plan", "estimate", "expect", "intend" or variations of such words and phrases or state that certain actions, events or results "may", "could", "would", "might", "will" or "will be taken", "occur" or "be achieved". In addition, any statements that refer to expectations, projections or other characterizations of future events or circumstances contain forward-looking information. Statements containing forward-looking information are not historical facts, but instead represent management's expectations, estimates and projections regarding future events. Forward-looking statements involve risks and uncertainties, including, but not limited to, the factors described in greater detail in the "Risks and Uncertainties" section of our management's discussion and analysis of financial condition and results of operations for the three and nine months ended June 30, 2022, which is available on the Company's profile at www.sedar.com, any of which could cause results, performance, or achievements to differ materially from the results discussed or implied in the forward-looking statements. Investors should not place undue reliance on any forward-looking statements. The forward-looking statements contained in this news release are made as of the date of this news release, and the Company assumes no obligation to update or alter any forward-looking statements, whether as a result of new information, further events or otherwise, except as required by law.

View original content to download multimedia:

<https://www.prnewswire.com/news-releases/covalon-announces-conference-call-to-discuss-fourth-quarter-and-year-end-fiscal-2022-financial-results-301727583.html>

SOURCE Covalon Technologies Ltd.

View original content to download multimedia: <http://www.newswire.ca/en/releases/archive/January2023/23/c8908.html>

%SEDAR: 00020909E

For further information: To learn more about Covalon, please contact: Brian Pedlar, CEO, Covalon Technologies Ltd, Email: bpedlar@covalon.com, Phone: 905.568.8400 x 233, Toll-Free: 1.877.711.6055

CO: Covalon Technologies Ltd.

CNW 07:00e 23-JAN-23